Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside

Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside

In contrast to external high energy photon or proton therapy, targeted radionuclide therapy (TRNT) is a systemic cancer treatment allowing targeted irradiation of a primary tumor and all its metastases, resulting in less collateral damage to normal tissues. The α-emitting radionuclide bismuth-213 (&...

Full description

Bibliographic Details
Main Authors: Stephen Ahenkorah, Irwin Cassells, Christophe M. Deroose, Thomas Cardinaels, Andrew R. Burgoyne, Guy Bormans, Maarten Ooms, Frederik Cleeren
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Pharmaceutics
Subjects:
bismuth-213
targeted radionuclide therapy
targeted alpha therapy
radiopharmaceutical
bifunctional chelator
vector molecule
Online Access:https://www.mdpi.com/1999-4923/13/5/599

Internet

https://www.mdpi.com/1999-4923/13/5/599

Similar Items